We welcome your support in Asiamoney Brokers Poll.

Please CLICK HERE to vote.



HCL Technologies

HOLD

Client specific challenges to impact near term growth

Summary

HCL Technologies (HCLT) reported weak results (revenue down 1.3% QoQ) mainly due to weakness in Tech & Telecom vertical. As highlighted in our IT thematic we were seeing weakness in HCL Tech clients. We continue to believe that macro challenges will impact company's near term revenue growth. Hence, we maintain our stance of company's revenue to be at the lower end of the guidance mainly led by lower ACV (down 21% YoY), client specific challenges and slowdown in discretionary spends. In addition, due to headwinds like wage hikes and lower ability to manage cost in uncertainty we have assumed margins at the lower end of guidance (18%). Consequently we have lowered our EPS estimates by 2% for FY25E. Hence, we maintain our HOLD rating on the stock with a revised target price of Rs 1100 (18x PE on FY25E EPS).

Key Highlights and Investment Rationale

- Conversion of deal pipeline challenging: HCL Technologies has reported weak ER&D revenues led by challenges in Tech & Telecom vertical. The company's deal wins has also decelerated from ~US\$2 bn to US\$1.6 bn and ACV down 21% YoY. The company is seeing acceleration in deal pipeline led by large deals across US & Europe, however, conversion of the same & ramp down in other projects remains key overhang in driving revenues. Even at a lower end of the guidance (CQGR of 2.5%) seems a tall task. Hence, we expect US\$ revenue CAGR of 7.5% over FY23-25E.
- Operating margins to remain range bound: The company has multiple levers like higher utilisation, pyramid utilisation and offshoring to drive margins. However, wage hike and lower revenues growth prompt us to keep margins in at 18.0% in FY24E & FY25E, respectively.

TP Rs	1,100
CMP Rs	1,110
Potential upside/downside	e -1%
Previous Rating	HOLD

Price Performance (%)								
-1m -3m -12								
Absolute	(2.6)	1.4	19.6					
Rel to Sensex	(6.8)	(6.9)	(1.7)					

V/s Consensus		
EPS (Rs)	FY24E	FY25E
IDBI Capital	56.6	61.1
Consensus	59.4	66.2
% difference	(4.8)	(7.7)

Key Stock Data	
Bloomberg/Reuters	HCLT IN/ HCLT.BC
Sector	IT Service
Shares o/s (mn)	2,714
Market cap. (Rs mn)	3,012,304
3-m daily avg Trd value	e (Rs mn) 86.8
52-week high / low	Rs1,203 / 876

Sensex / Nifty

Shareholding Pattern (%)	
Promoters	60.8
FII	18.9
DII	14.5
Public	5.8

Financial snapshot

(Rs mn)

65,394 / 19,384

Year	FY21	FY22	FY23	FY24E	FY25E
Revenue	7,53,790	8,56,510	10,14,560	10,96,005	11,96,232
Change (yoy, %)	7	14	18	8	9
EBITDA	2,07,750	2,05,300	2,26,280	2,40,699	2,66,037
Change (yoy, %)	24	(1)	10	6	11
EBITDA Margin (%)	27.6	24.0	22.3	22.0	22.2
Adj. PAT	1,29,410	1,34,990	1,46,870	1,53,759	1,65,867
EPS (Rs)	47.7	49.7	54.1	56.6	61.1
Change (yoy, %)	18	4	9	5	8
PE(x)	23	22	21	20	18
Dividend Yield (%)	2	4	4	4	5
EV/EBITDA (x)	14	14	13	12	10
RoE (%)	23.3	22.2	23.1	23.0	23.7
RoCE (%)	26	24	26	27	28
Course IDDI Canital Basearch					

Source: IDBI Capital Research;

Devang Bhatt

devang.bhatt@idbicapital.com +91-22-2217 1846

Dhawal Doshi

dhawal.doshi@idbicapital.com +91-22-2217 1841



Other Key Highlights

- Revenue in CC terms was down 1.3% QoQ & up by 6.3% YoY. Services revenue was down 1% QoQ due to demand softness in large verticals, project ramp downs & reduced discretionary spends.
- EBIT margin declined on QoQ basis by 110 bps from 18.1% to 17%. Software segment margin growth was flat QoQ as the negative impact of revenue decline was offset by onetime benefit from amortization reversal of intangible assets. Services margin dropped by 120 bps on the back of 10bps impact due to forex, 36 bps impact due to reduced utilisation, 33 bps impact due to travel and other costs and 42 bps impact due to the presence of one-time benefit in previous quarter numbers which was absent during Q1FY24.
- In terms of Segmental performance , IT and Business services had good momentum on new deals signed but most were offsets with reduction in discretionary spend leading to flat QoQ revenues in CC. ER&D services saw QoQ contraction by 5.2% due to deal ramp downs. Management informed that this segment has now stabilized. Software revenue was stable YoY in CC terms.
- In terms of Industry verticals, Financial services grew 5.1% sequentially & 14.4% YoY in CC, Manufacturing grew 3.6% sequentially & 16.5% YoY, life sciences grew 13.4% YoY this has been due to great execution of large deals which translated into revenue which has helped in offset of discretionary spend reduction in these vertical. Tech and Telecom vertical saw significant decline primary driven by cuts in discretionary spend and associated ramp downs.
- In terms of geography, US reported flat growth; Europe & ROW reported negative growth on a constant currency basis sequentially. TCV of new deal wins at \$1.6bn was soft on a QoQ basis. Management expects some spike in coming quarters. Pipeline remain strong (+17.7% QoQ and +26.2% YoY).
- Company won 18 large deals (11 in software & 7 large deals in services). Company guided that despite the demand environment being challenging, it is confident of achieving its FY24 revenue growth guidance of 6%-8% YoY in CC terms (services revenue growth expects to be 6.6%-8.5% YoY in CC terms) as it expects growth to pick up in the coming quarters given the strong pipeline. EBIT margin is expected to be between 18%-19%. We believe inorganic growth could also drive revenues.
- The company has made an acquisition of ASAP group (an Auto ER&D company) for Euro 251 mn and revenue of Euro 154 mn. Acquisition is expected to be completed by September 2023.



Exhibit 1: Financial snapshot

(Rs mn)

Year-end: March	Q1FY24	Q4FY23	QoQ (%)	Q1FY23	YoY (%)
Revenues (US\$ mn)	3,200	3,235	(1.1)	3,025	5.8
Revenues	2,62,960	2,66,060	(1.2)	2,34,640	12.1
COGS	1,73,300	1,73,270	0.0	1,54,570	12.1
Gross profit	89,660	92,790	(3.4)	80,070	12.0
SG&A	35,790	34,160	4.8	30,320	18.0
EBITDA	53,870	58,630	(8.1)	49,750	8.3
Depreciation & amortization	9,270	10,270	(9.7)	9,830	(5.7)
EBIT	44,600	48,360	(7.8)	39,920	11.7
Other income	2,360	3,590	(34.3)	3,450	(31.6)
PBT	46,960	51,950	(9.6)	43,370	8.3
Tax	11,650	12,140	(4.0)	10,560	10.3
Minority interest	-30	-20	n.m.	-20	n.m.
Reported net profit	35,340	39,830	(11.3)	32,830	7.6
Diluted EPS (Rs)	13.1	14.7	(11.3)	12.1	7.6
As % of net revenue					
Gross profit	34.1	34.9		34.1	34.1
SG&A	13.6	12.8		12.9	13.6
EBITDA	20.5	22.0		21.2	20.5
EBIT	17.0	18.2		17.0	17.0
Reported net profit	13.4	15.0		14.0	13.4
Tax rate	24.8	23.4		24.3	24.8
Source: Company: IDRI Canital Research					



Exhibit 2: Earnings Revision

		FY24F			FY25E		
Year-end: March	New	Old	Chg (%)	New	Old	Chg (%)	
Revenue (US\$ mn)	13,334.4	13,340.5	(0.0)	14,552.7	14576.2	(0.2)	
Revenue (Rs bn)	1,096.0	1,096.6	(0.1)	1,196.2	1198.2	(0.2)	
EBIT (Rs bn)	197.3	198.7	(0.7)	215.8	219.6	(1.7)	
EBIT margin (%)	18.00	18.12	(12) bps	18.04	18.32	(28)bps	
EPS (Rs)	56.6	56.4	0.4	61.1	62.3	(1.9)	

Exhibit 3: Actual vs. estimates

Year to March	Q1FY24	Q1FY24E	Variance (%)
Revenue (US\$ mn)	3,200	3,243	(1.3)
Revenue (Rs mn)	2,62,960	2,66,574	(1.4)
EBIT (Rs mn)	44,600	47,200	(5.5)
EBIT margin (%)	17.0%	17.7%	(75)bps
PAT (Rs mn)	35,340	36,827	(4.0)
PAT margin (%)	13.4%	13.8%	38bps
EPS (Rs)	13.1	13.6	-4.0



Exhibit 4: Q1FY24 revenue growth was impacted by demand softness




Exhibit 5: Growth in large clients

Year-end: March	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24
US\$100m +	15	15	16	17	17	17	19	20
US\$50m +	41	42	43	42	42	45	46	48
US\$20m +	109	110	118	127	128	130	131	127
US\$10m +	190	198	208	218	220	221	229	237
US\$5m +	329	346	349	353	356	365	375	390
US\$1m +	836	864	882	880	890	937	939	947



Exhibit 6: Revenue growth across various segments (%)

Parameters	% of revenue	QoQ CC growth	YoY CC growth
Overall revenue growth		-1.3	6.3
Geography		-1.3	6.3
US	64.5	0.2	7.3
Europe	28.7	(2.4)	10.5
ROW	6.8	(6.2)	(6.0)
Service-lines			
IT and Business services	73.8	(0.1)	9.1
Engineering and R&D Services	16.1	(5.2)	(1.8)
Products and Platforms	10.1	(3.1)	(0.1)
Verticals			
Financial Services	22.6	5.1	14.4
Manufacturing	19.9	3.6	16.5
Technology & Services	13.4	(7.8)	(7.0)
Telecom &Media Publishing	7.6	(14.4)	(11.7)
Retail & CPG	9.1	0.3	3.2
Life science & Healthcare	17.5	(1.3)	13.4
Public Services	10.0	(2.2)	6.8



Exhibit 7: Q1FY24 EBIT margin declined by 120 bps QoQ




Exhibit 8: SG&A saw a QoQ rise







Exhibit 9: One-year forward PER trend





Financial Summary

Profit & Loss Account (Rs mn)

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Net sales	7,06,780	7,53,790	8,56,510	10,14,560	10,96,005	11,96,232
Change (yoy, %)	17	7	14	18	8	9
Operating expenses	(5,39,850)	(5,46,040)	(6,51,210)	(7,88,280)	(8,55,306)	(9,30,196)
EBITDA	1,66,930	2,07,750	2,05,300	2,26,280	2,40,699	2,66,037
Change (yoy, %)	20	24	-1	10	6	11
Margin (%)	23.6	27.6	24.0	22.3	22.0	22.2
Depreciation	(28,400)	(46,110)	(43,260)	(41,450)	(43,383)	(50,251)
EBIT	1,38,530	1,61,640	1,62,040	1,84,830	1,97,316	2,15,786
Interest paid	-	-	-	-	-	-
Other income	1,790	4,160	7,470	8,410	10,210	9,440
Pre-tax profit	1,40,320	1,65,800	1,69,510	1,93,240	2,07,526	2,25,226
Tax	(30,748)	(36,150)	(34,280)	(46,420)	(53,197)	(58,559)
Effective tax rate (%)	21.9	21.8	20.2	24.0	25.6	26.0
Minority Interest	(320.0)	(240.0)	(240.0)	50.0	(570.0)	(800.0)
Net profit	1,09,252	1,29,410	1,34,990	1,46,870	1,53,759	1,65,867
Exceptional items	-	-	-	-	-	-
Adjusted net profit	1,09,252	1,29,410	1,34,990	1,46,870	1,53,759	1,65,867
Change (yoy, %)	8	18	4	9	5	8
EPS	40.3	47.7	49.7	54.1	56.6	61.1
Dividend per sh	6	26	44	48	45	50
Dividend Payout %	18	55	88	89	79	82



Balance Sheet						(Rs mn)
Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Shareholders' funds	5,12,670	5,99,130	6,19,140	6,54,050	6,85,634	7,15,751
Share capital	5,427	5,427	5,430	5,430	5,430	5,430
Reserves & surplus	5,07,243	5,93,703	6,13,710	6,48,620	6,80,204	7,10,321
Total Debt	46,930	38,280	39,230	21,110	21,110	21,110
Other liabilities	25,900	37,200	31,530	32,190	58,138	64,453
Curr Liab & prov	2,18,850	1,73,830	1,87,750	2,14,310	2,27,974	2,48,562
Current liabilities	2,01,100	1,51,370	1,64,820	1,81,610	1,95,527	2,12,611
Provisions	17,750	22,460	22,930	32,700	32,447	35,951
Total liabilities	2,91,680	2,49,310	2,58,510	2,67,610	3,07,222	3,34,124
Total equity & liabilities	8,05,890	8,50,130	8,78,570	9,21,590	9,93,356	10,51,176
Net fixed assets	3,52,420	3,50,470	3,29,010	3,23,220	3,09,802	2,89,551
Investments	770	890	1,030	1,100	1,100	1,100
Other non-curr assets	66,700	68,260	68,120	61,500	99,091	1,08,152
Current assets	3,86,000	4,30,510	4,80,410	5,35,770	5,83,364	6,52,372
Inventories	910	940	1,610	2,280	1,501	1,639
Sundry Debtors	1,41,310	1,36,630	1,54,760	1,95,720	2,11,394	2,30,725

1,56,610

8,50,130

48,410

1,88,750

8,78,570

30,080

2,01,090

9,21,590

26,030

2,22,816

9,93,356

28,120

1,19,650

8,05,890

34,220

Cash and Bank

Total assets

Loans and advances

2,58,853

10,51,176

30,691



Cash Flow Statement						(Rs mn
Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Pre-tax profit	1,40,320	1,65,800	1,69,510	1,93,240	2,07,526	2,25,226
Depreciation	19,000	46,110	43,260	41,450	43,383	50,251
Tax paid	(30,758)	(24,190)	(34,580)	(46,690)	(53,197)	(58,559)
Chg in working capital	57,750	(54,560)	13,450	(11,020)	(3,321)	(1,453)
Other operating activities	(17,980)	27,375	(18,043)	20,470	(20,525)	(13,678)
Cash flow from operations (a)	1,68,331	1,60,535	1,73,597	1,97,450	1,79,297	2,01,787
Capital expenditure	(1,40,190)	(44,160)	(21,800)	(35,660)	(29,965)	(30,000)
Chg in investments	80	(120)	(140)	(70)	-	-
Other investing activities	-	-	-	-	-	-
Cash flow from investing (b)	(1,40,110)	(44,280)	(21,940)	(35,730)	(29,965)	(30,000)
Equity raised/(repaid)	2	-	3	-	-	-
Debt raised/(repaid)	9,920	(8,650)	950	(18,120)	-	-
Dividend (incl. tax)	(19,604)	(70,555)	(1,19,460)	(1,30,320)	(1,22,175)	(1,35,750)
Chg in minorities	190	(90)	(1,010)	(940)	-	-
Other financing activities	-	-	-	-	-	-
Cash flow from financing (c)	(9,491)	(79,295)	(1,19,517)	(1,49,380)	(1,22,175)	(1,35,750)
Net chg in cash (a+b+c)	18,730	36,960	32,140	12,340	21,727	36,037



Financial Ratios

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Book Value (Rs)	189	221	228	241	253	264
Adj EPS (Rs)	40.3	47.7	49.7	54.1	56.6	61.1
Adj EPS growth (%)	8	18	4	9	5	8
EBITDA margin (%)	24	28	24	22	22	22
Pre-tax margin (%)	20	22	20	19	19	19
Net Debt/Equity (x)	0	0	0	0	0	0
ROCE (%)	27	26	24	26	27	28
ROE (%)	23.6	23.3	22.2	23.1	23.0	23.7
DuPont Analysis						
Asset turnover (x)	1.0	0.9	1.0	1.1	1.1	1.2
Leverage factor (x)	1.5	1.5	1.4	1.4	1.4	1.5
Net margin (%)	15.5	17.2	15.8	14.5	14.0	13.9
Working Capital & Liquidity ratio						
Inventory days	0	0	1	1	1	1
Receivable days	73	66	66	70	70	70
Payable days	8	12	13	12	12	12

Valuations

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
PER (x)	27.6	23.3	22.3	20.5	19.6	18.2
Price/Book value (x)	5.9	5.0	4.9	4.6	4.4	4.2
EV/Net sales (x)	4.2	3.8	3.3	2.8	2.6	2.3
EV/EBITDA (x)	18	14	14	13	12	10
Dividend Yield (%)	1	2	4	4	4	5





Dealing (91-22) 6836 1111 dealing@idbicapital.com

Key to Ratings Stocks:

BUY: 15%+; **HOLD:** -5% to 15%; **SELL:** -5% and below.

IDBI Capital Markets & Securities Ltd.

Equity Research Desk

6th Floor, IDBI Tower, WTC Complex, Cuffe Parade, Colaba, Mumbai – 400 005. Phones: (91-22) 2217 1700; Fax: (91-22) 2215 1787; Email: info@idbicapital.com

SEBI Registration: BSE & NSE (Cash & FO) - INZ000007237, NSDL - IN-DP-NSDL-12-96, Research - INH000002459, CIN - U65990MH1993GOI075578

Compliance Officer: Christina D'souza; Email: compliance@idbicapital.com; Telephone: (91-22) 2217 1907

Disclaimer

This report has been published by IDBI Capital Markets & Securities Ltd.(hereinafter referred to as "IDBI Capital") for private circulation. This report should not be reproduced or copied or made available to others. No person associated with IDBI Capital is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this report. The information contained herein is strictly confidential and meant for solely for the selected recipient and may not be altered in any way, transmitted to copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without the prior written consent of IDBI Capital.

Recipients may not receive this report at the same time as other recipients. IDBI Capital will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is from the public domain or sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be reliable upon as such. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be reliable upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Opinions expressed are current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis, the information discussed in this material, IDBI Capital, its directors, employees are under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent us from doing so.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

IDBI Capital, its directors and employees and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report.

This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behavior of investors or recipients or provide any investment/tax advice.

This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis.

Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital.

Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of IDBI Capital, its directors, officers, or employees.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IDBI Capital and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this report may come are required to inform themselves of and to observe such restriction.

E-mail is not a secure method of communication. IDBI Capital cannot accept responsibility for the accuracy or completeness of any e-mail message or any attachment(s).

This transmission could contain viruses, be corrupted, destroyed, incomplete, intercepted, lost or arrived late. IDBI Capital, its directors or employees or associates accept no liability for any damage caused, directly or indirectly, by this email.



Analyst Disclosures

We, Devang Bhatt and Dhawal Doshi, hereby certify that the views expressed in this report accurately reflect our personal views about the subject companies and / or securities. We also certify that no part of our compensation were, are or would be directly or indirectly related to the specific recommendations or views expressed in this report. Principally, We will be responsible for the preparation of this research report and have taken reasonable care to achieve and maintain independence and objectivity in making any recommendations herein.

Other Disclosure

IDBI Capital Markets & Securities Ltd. (herein after referred to as "IDBI Capital") was incorporated in the year 1993 under Companies Act, 1956 and is a wholly owned subsidiary of IDBI Bank Limited. IDBI Capital is one of India's leading securities firm which offers a full suite of products and services to individual, institutional and corporate clients namely Stock broking (Institutional and Retail), Distribution of financial products, Merchant Banking, Corporate Advisory Services, Debt Arranging & Underwriting, Portfolio Manager Services and providing Depository Services. IDBI Capital is a registered trading and clearing member of BSE Ltd. (BSE) and National Stock Exchange of India Limited (NSE). IDBI Capital is also a SEBI registered Merchant Banker, Portfolio Manager and Research Analyst. IDBI Capital is also a SEBI registered depository participant with National Securities Depository Limited (NSDL) and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI).

IDBI Capital and its associates IDBI Bank Ltd. (Holding Company), IDBI Intech Ltd. (Fellow Subsidiary), IDBI Asset Management Ltd. (Fellow Subsidiary) and IDBI Trusteeship Services Ltd. (Fellow Subsidiary).

IDBI Group is a full-serviced banking, integrated investment banking, investment management, brokerage and financing group. Details in respect of which are available on www.idbicapital.com IDBI Capital along with its associates are leading underwriter of securities and participants in virtually all securities trading markets in India. We and our associates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department. Investors should assume that IDBI Capital and/or its associates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material. IDBI Capital generally prohibits its analysts, persons reporting to analysts, and their dependent family members having a financial conflict of interest in the securities or derivatives of any companies that the analysts cover. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Directors of IDBI Capital and the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of IDBI Capital. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice

IDBI Capital hereby declares that our activities were neither suspended nor we have materially defaulted with any Stock Exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on IDBI Capital, for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time. IDBI Capital, its directors or employees or associates, may from time to time, have positions in, or options on, and buy and sell securities referred to herein. IDBI Capital or its associates, during the normal course of business, from time to time, may solicit from or perform investment banking or other services for any company mentioned in this document or their connected persons or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or their affiliate companies or act as advisor or lender / borrower to such company(ies)/associates companies or have other potential conflict of interest. This report may provide hyperlinks to other websites. Except to the extent to which the report refers to the websites of IDBI Capital, IDBI Capital states that it has not reviewed the linked site and takes no responsibility for the content contained in such other websites. Accessing such websites shall be at recipient's own risk. IDBI Capital encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. Accordingly, neither IDBI Capital or Research Analyst have any material conflict of interest at the time of publication of this report. We offer our research services to primarily institutional inve